Amgen Announces New FOURIER Analysis Showing Benefit With Repatha ® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease

Repatha Results in Consistent Reductions in LDL-C Levels and Cardiovascular Events in Patients Independent of Kidney Function Results Presented at American Society of Nephrology Kidney Week 2018 THOUSAND OAKS, Calif., Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha® (evolocumab) in patients with established cardiovascular disease by kidney function. In line with previous FOURIER subgroup analyses, these results further demonstrate Repatha's efficacy in reducing not only low-density lipoprotein cholesterol (LDL-C) levels, but also the relative risk for major cardiovascular...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news